AstraZeneca may resume its halted trial of its COVID-19 vaccine as early as next week, the Financial Times reported, citing people familiar with the matter. The company halted the trial after the discovery of a sick participant, who contracted transverse myelitis, the report said. The trial may see further pauses, the report said, citing a person close to the process.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.